Key result
Community- and hospital-acquired hypernatraemia are linked to up to ~391% higher hospital mortality.
Why the study?
The short-term and long-term mortality associated with community- and hospital-acquired hypernatraemia and the impact of delayed serum sodium correction in hospitalized patients were not well characterized.
Does community- or hospital-acquired hypernatraemia and delayed serum sodium correction increase mortality in hospitalized adults?
Cohort (n=25,781)
No
Does community- or hospital-acquired hypernatraemia and delayed serum sodium correction increase mortality in hospitalized adults?
Odds Ratio: 4.91 (95% CI 3.47–6.94)
Hypernatraemia, regardless of origin, and failure to correct it by hospital day 3 are associated with elevated short-term and long-term mortality.
Hypernatraemia and delayed correction may flag higher short- and long-term mortality risk; leaves open whether timely correction improves outcomes in observational data.
BACKGROUND: This study examined the short-term and long-term mortality of community- and hospital-acquired hypernatraemia in a large cohort of general hospitalised patients, and the impact of delayed serum sodium correction in hypernatraemic patients. METHODS: Adult patients admitted to Mayo Clinic Rochester from 2011 to 2013 were examined. The patients with admission serum sodium ≥138 mEq/L and at least 2 serum sodium measurements during hospitalisation were included. Hypernatraemia was defined as serum sodium ≥143 mEq/L. The patients were categorised into three groups based on serum sodium at admission and during hospitalisation: (a) normal serum sodium, (b) community-acquired hypernatraemia and (c) hospital-acquired hypernatraemia. Outcomes included hospital mortality and 1-year mortality after hospital discharge amongst hospital survivors. RESULTS: Of 25 781 eligible patients, 45% had normal serum sodium, 20% had community-acquired hypernatraemia and 35% had hospital-acquired hypernatraemia. In adjusted analysis, odds ratios (ORs) of community- and hospital-acquired hypernatraemia for hospital mortality were 4.91 (95% CI 3.47-6.94) and 4.11 (95% CI 2.94-5.73), whereas hazard ratio (HR) for 1-year mortality was 1.76 (95% CI 1.56-1.98) and 1.61 (95% CI 1.45-1.79), respectively. Hospital-acquired hypernatraemia had a higher hospital mortality but not 1-year mortality than community-acquired hypernatraemia. In patients with community-acquired hypernatraemia, 36% remained hypernatraemic by hospital day 3. Hospital mortality (OR 3.01; 95% CI 2.71-5.83) and 1-year mortality (HR 1.51; 95% CI 1.26-1.81) were significantly increased in patients with persistent hypernatraemia, compared with those with serum sodium correction into optimal range of 138-142 mEq/L. CONCLUSION: Hypernatraemia, regardless of acquisition origin, is associated with elevated short-term and long-term mortality. Hospital-acquired hypernatraemia was more common and had a higher short-term mortality than community-acquired hypernatraemia. Failure to correct hypernatraemia by hospital day 3 is associated with increased mortality.
No takes yet. Share an insight, caveat, or question.
Thongprayoon et al. (2021) conducted a cohort in Hypernatraemia (n=25,781). Community- and hospital-acquired hypernatraemia vs. Normal serum sodium was evaluated on Hospital mortality (OR 4.91, 95% CI 3.47-6.94). Community- and hospital-acquired hypernatraemia were associated with increased hospital mortality (OR 4.91; 95% CI 3.47-6.94 and OR 4.11; 95% CI 2.94-5.73, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: